What one share of Bolt Biotherapeutics holds
Our mission is to harness the power of the immune system to improve lives and eradicate cancer. This often means that our product candidates take new and unproven approaches to treating cancer. We believe that taking smart risks is critical to making breakthroughs.
Bolt Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.68 |
|---|---|
| Profit | −$16.37 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$17.97 |
| Cash and investments | $6.68 |
| Book value | $6.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $2.32 | −$577.80 | $32.80 | −$508.44 | — | −$985.35 |
| 2021 | $0.76 | −$59.40 | $1.41 | −$35.79 | — | $133.75 |
| 2022 | $3.07 | −$47.16 | $1.05 | −$42.00 | — | $90.75 |
| 2023 | $4.17 | −$36.60 | $0.11 | −$36.88 | — | $59.16 |
| 2024 | $4.03 | −$33.06 | $0.02 | −$32.12 | — | $29.84 |
| 2025 | $4.12 | −$17.85 | $0.04 | −$21.35 | — | $13.80 |
Common questions about Bolt Biotherapeutics
How much does one share of Bolt Biotherapeutics earn?
Over the last 12 months, Bolt Biotherapeutics lost $16.37 for each share on $2.68 of sales.
Does Bolt Biotherapeutics pay a dividend?
Bolt Biotherapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Bolt Biotherapeutics’s book value per share?
Bolt Biotherapeutics’s book value is $6.56 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Bolt Biotherapeutics have?
Each share of Bolt Biotherapeutics has $6.68 of cash and investments, as of June 30, 2026.
What is Bolt Biotherapeutics’s free cash flow per share?
−$17.97 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Bolt Biotherapeutics bought back shares?
Bolt Biotherapeutics’s share count rose about 1780% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.